NCT00073892 - PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Melanoma (Skin)Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

PI-88

250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle

Trial Locations (5)

Alfred Hospital, Melbourne

Princess Alexandra Hospital, Brisbane

Queen Elizabeth Hospital, Woodville

Sir Charles Gairdner Hospital - Perth, Perth

University of Colorado Cancer Center at University of Colorado Health Sciences Center, Aurora